Crafting a campaign identity grounded in a decade of evidence

Create a premium anniversary identity that celebrates a decade of clinical evidence while positioning ELUVIA as the benchmark for confidence, trust and long-term performance. Peripheral artery disease (PAD) affects more than 110 million people worldwide, and peripheral stents alone are a market worth around $5.75bn a year. When ELUVIA received its CE mark in 2016, it was the first polymer-based drug-eluting stent for blockages above the knee approved in Europe.

Avoid conventional anniversary branding by creating a quality mark that could become a recognisable campaign identifier across every touchpoint.